Thompson Rivers University officials say it was an "erratically high" rate of study permits being issued by the federal ...
Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback